טוען...
New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups
OBJECTIVES: The new direct-acting antivirals (DAAs) have changed chronic hepatitis C virus (HCV) treatment perspectives by achieving success rates in all genotypes and by reducing the associated adverse effects in comparison to pegylated interferon α regimens. These adverse effects include depressio...
שמור ב:
| הוצא לאור ב: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Publishing Group
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6684011/ https://ncbi.nlm.nih.gov/pubmed/31428320 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2017-001352 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|